Skip to content

Moderna and Merck say mRNA vaccine prevents melanoma relapse in trial

scienceAug 19, 20264511,565

Moderna and Merck reported that their personalized mRNA vaccine, intrismeran, reduced melanoma recurrence and metastasis in a late-stage (phase 3) trial of more than 1,100 high-risk melanoma patients. The vaccine is made for each patient by sequencing mutations in the patient’s tumor and using mRNA to train the immune system, and was tested in combination with Merck’s checkpoint inhibitor Keytruda. Company statements said the treatment significantly extended the time patients lived without their melanoma returning and lowered the risk that the cancer would spread. The announcements give only a broad outline of results rather than full trial data or a peer-reviewed paper. Observers and news coverage noted that the field now awaits the detailed numbers and formal data release to evaluate effect sizes and safety fully.

Chise
@sailorrooscout.bsky.social

GOOD NEWS! A personalized mRNA vaccine has SUCCEEDED in keeping melanoma, a deadly skin cancer, from returning. Phase III trial results in MORE THAN 1,100 patients shows the vaccine SIGNIFICANTLY extended the time patients lived without their melanoma returning AND reduced the risk of metastasis.

435845d ago
altNOAA 🇺🇸
@altnoaa.bsky.social

American drug companies Merck and Moderna have created a vaccine that has stopped skin cancer returning in patients during a trial. Each vaccine is created specifically for an individual patient by sequencing DNA from patient's tumor and using mRNA to create the vaccine.

364645d ago
Dr. Lucky Tran
@luckytran.com

Scientists are making huge breakthroughs using mRNA vaccines to treat melanoma, pancreatic cancer, and other cancers. Meanwhile, RFK Jr has cancelled $500 million in funding for mRNA vaccine research. “Make America Healthy Again”

60345d ago
1 source